Cargando...
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Immune checkpoint inhibitors have emerged as a mainstay of melanoma therapy and are playing an increasingly important role in the treatment of other tumor types. The clinical benefit afforded by these treatments can be accompanied by a unique spectrum of adverse events, called immune-related adverse...
Gardado en:
| Publicado en: | Oncologist |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado: |
AlphaMed Press
2016
|
| Assuntos: | |
| Acceso en liña: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5061539/ https://ncbi.nlm.nih.gov/pubmed/27401894 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2016-0055 |
| Tags: |
Engadir etiqueta
Sen Etiquetas, Sexa o primeiro en etiquetar este rexistro!
|